An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday. A weekly shot form of Leqembi, given as two consecutive injections,...
An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday.
The intravenous form of Leqembi won U.S. approval based on that larger 18-month study showing the drug, which works by removing sticky clumps of beta amyloid from the brain, slowed cognitive decline by 27% for people with early Alzheimer's disease. “The idea of having a much more accessible self-administered, subcutaneous treatment is very important for this class of drugs. The data was very encouraging,” said Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute, who was not affiliated with the clinical trial.
ARIA-H, or brain bleeding, occurred in 22.2% of the subcutaneous patients versus 17.3% of the IV group. Eisai and U.S. partner Biogen said they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March based on data from 394 patients.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggestsThe Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests, potentially providing a more convenient way for patients to get treatment.
Read more »
Biogen and Eisai release new Alzheimer’s drug data that may support wider uptakeEisai plans to apply for FDA approval of subcutaneous Leqembi by early next year
Read more »
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Read more »
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
Read more »
Flu shots may protect against the risk of Alzheimer’s, related dementiasSome studies have shown that vaccinated individuals appear less likely than the unvaccinated to develop dementia, although scientists aren’t sure why.
Read more »
Common Fungus Linked to Alzheimer's DiseaseA disturbing new study found that the common fungus Candida albicans (C. albicans) can enter the brain and trigger a cascade of events that may lead to Alzheimer's disease. Scientists from Baylor College of Medicine reveal that as the brain endeavors to clear the fungus,...
Read more »